Sun Pharmaceutical Industries Ltd Share Price Today

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 500% at ₹5/Share	07-Jul-2026	07-Jul-2026
DividendsInterim Dividend of 1100% at ₹11/Share	05-Feb-2026	05-Feb-2026
DividendsFinal Dividend of 550% at ₹5.5/Share	07-Jul-2025	07-Jul-2025
DividendsInterim Dividend of 1050% at ₹10.5/Share	06-Feb-2025	06-Feb-2025

Mutual Fund Holder	Jul 26 Shares held	Aug 26 Shares held
SBI Nifty 50 ETF	2.04 Cr	2.05 Cr (0.53%)
SBI BSE Sensex ETF	1.43 Cr	1.44 Cr (1%)
ICICI Prudential Value Fund - Growth	1.38 Cr	1.38 Cr no change
ICICI Prudential Aggressive Hybrid Fund - Growth	-	98.53 Lac (100%)
ICICI Prudential Large Cap Fund - Growth	90.69 Lac	90.69 Lac no change

Sumit Kadam

17 Sep • 4:40 PM · SEBI-Registered Analyst

Peak XV Sells ₹1,756 Crore Groww Stake what investors learn

Imagine an early investor entering a business when most people have never heard of it. Years later, that business becomes a listed market leader—and the early investor starts booking returns through block deals. That is the story unfolding around **Billionbrains Garage Ventures, the parent company of

GROWW

**. Peak XV Partners sold **9.17 crore shares, representing a 1.46% stake, for approximately ₹1,756 crore at an average ₹191.49 per share**. Its holding consequently declined from 15.68% to 14.22%, while it remained the largest public shareholder. But there is another side to the story. Billionbrains reported **Q1 FY27 revenue of ₹1,501 crore, up 66% YoY, while net profit increased 94% to ₹735 crore**. A large shareholder may sell for portfolio rebalancing, liquidity, profit realisation, or other strategic reasons. The better lesson is to separate **ownership activity from business performance**. This framework can also be applied when studying Nifty 500 companies such as **HDFC Bank, ICICI Bank, Bajaj Finance, Trent, Bharat Electronics, Sun Pharma and Tata Motors**. Before forming an investment view, investors can examine: 📊 Shareholding changes 📈 Revenue and profit growth 💰 Cash flows and balance-sheet strength 🏭 Business outlook and industry trends 📉 Valuation and market price behaviour A large stake sale deserves attention, but investors should evaluate business fundamentals, valuation, ownership trends and financial performance together. **Educational Disclaimer:** This content is for educational and informational purposes only. It is not a stock tip, investment recommendation, or investment advice. The securities mentioned are examples for learning purposes only. Investors should conduct independent research and consult a SEBI-registered investment adviser before making investment decisions.

Umang Bhutada

15 Sep • 1:15 PM · SEBI-Registered Analyst

Sun Pharma: US Generic Drug Litigation Settled

Sun Pharmaceutical Industries (

SUNPHARMA

) is in focus after the company and its subsidiaries entered into a settlement agreement in the US Generic Pharmaceuticals Pricing Antitrust Litigation. Key Points • Settlement reached in US generic-pharmaceutical pricing litigation • Agreement covers Sun Pharma and its relevant subsidiaries • Provides a full release of claims against the company and subsidiaries • Financial settlement amount remains confidential • Removes an ongoing litigation overhang from the company's risk profile Technical View The settlement is a corporate-risk development rather than an immediate operating catalyst. Investors will likely focus on the absence of further litigation uncertainty and the eventual financial implications, if disclosed. Alpha Insight For large pharma companies, resolution of major US litigation can reduce legal uncertainty. The key point here is that the settlement provides a full release while the financial terms remain confidential. For educational and informational purposes only. Not investment advice. UMANG RAJESH BHUTADA SEBI Registered Research Analyst Registration No. INH000023001 SEBI registration does not guarantee returns or profits.

DEEPAK PAL

15 Sep • 9:10 AM · SEBI-Registered Analyst

“Crude और Fed के बीच आज Market में Volatility का इम्तिहान!”

Crude Oil: Brent करीब $107 पर है। महंगा crude आज भी market का सबसे बड़ा risk है—OMCs, aviation, paints और chemicals पर pressure रहेगा। US Fed: आज से Fed meeting शुरू हो रही है। Rate decision और commentary से global markets में volatility बढ़ सकती है। Rupee: ₹95.55/$ के आसपास कमजोर rupee; crude और Fed outlook के कारण pressure जारी रह सकता है। Nifty: शुक्रवार के 23,398 close के बाद आज GIFT Nifty positive opening संकेत दे रहा है। 23,230 support, जबकि 23,600–23,620 resistance अहम रहेगा। Stocks in Focus: HDFC Bank, Sun Pharma, Aurobindo Pharma, HDFC Life, Coforge,

KEC

KEC International, Waaree Renewable। HDFC Bank में CEO succession update खास trigger है। FII-DII: FII selling pressure जारी, लेकिन DII buying market को support दे रही है।

Vimal K

15 Sep • 9:09 AM · SEBI-Registered Analyst

Sunpharma Secure Settlement in U.S. Generic Drug Price

Sun Pharma Subsidiaries Secure Settlement in Major U.S. Generic Drug Price-Fixing Antitrust Litigation : - In a significant legal development aimed at clearing long-standing regulatory and litigation hurdles in its largest overseas market, Sun Pharmaceutical Industries Limited announced that its key North American subsidiaries have entered into a confidential settlement agreement. The deal effectively resolves a major subset of claims within the massive, multi-district litigation known as In re Generic Pharmaceuticals Pricing Antitrust Litigation, currently pending in the United States District Court for the Eastern District of Pennsylvania. The agreement involves three prominent arms of India's largest drugmaker: Sun Pharmaceutical Industries Inc. (SPII), Taro Pharmaceutical Industries Ltd., and Taro Pharmaceuticals U.S.A., Inc. While the exact financial terms and payout figures of the settlement remain strictly confidential under the provisions of the contract, the resolution marks a strategic milestone for the pharmaceutical giant as it systematically de-risks its corporate liabilities in the United States.

SUNPHARMA

saurabh mittal

14 Sep • 5:01 PM · SEBI-Registered Analyst

Sun Pharmaceutical Industries Ltd US antitrust settlement

SUNPHARMA

Sun Pharma disclosed that its US subsidiaries—Sun Pharma Inc. and Taro Pharmaceuticals—have reached a settlement with a plaintiff in the long‑running US generic‑drug pricing antitrust litigation. The settlement provides a full release of all claims against the subsidiaries and related parties, is without admission of wrongdoing, and the amount is confidential. The case dates back to 2016 and alleged anticompetitive conduct by several generic drugmakers. Bernstein maintains an Outperform rating with a target price of ₹2,235 on Sun Pharma, noting management’s focus on integrating Organon and harvesting synergies rather than special dividends or buybacks in FY27–29. The stock has been under mild pressure, slipping to around ₹1,842 in recent sessions, partly weighed by the antitrust overhang.

Dhwani Patel

11 Sep • 11:15 AM · SEBI-Registered Analyst

Sun Pharma - Why a cloud breakdown is read differently

SUNPHARMA

closed at 1843.10, lower by 17.90 or 0.96%. The Ichimoku readings are Tenkan at 1901.10, Kijun at 1911.90, Span A at 1906.50 and Span B at 1943.00. The cloud therefore spans 1906.50 to 1943.00, and price has closed beneath it. There is a reason Ichimoku practitioners treat this differently from a simple average break. A moving average is a single line, so a break is a single event. The cloud is a zone, and price must travel through the entire thickness of it before the signal is considered complete. Here the stock has done exactly that. It traded inside the cloud through early September and has now exited the lower edge. Two supporting details are worth noting. Tenkan at 1901.10 is below Kijun at 1911.90, which means the shorter-term midpoint has slipped under the longer-term one. And the cloud ahead is red, with Span A below Span B, so the zone price would have to reclaim is not a thin one. The fundamental backdrop explains why the stock had the earlier advance and why it is being reassessed now. The specialty portfolio, Ilumya and Winlevi in particular, has been the growth engine that separated Sun from a purely generic story. The US generics side remains price competitive, and every quarter the market weighs how much of the specialty ramp is offsetting that. A pullback of this kind often coincides with the market pausing to check the arithmetic rather than abandoning the thesis.

Sun Pharmaceutical Industries Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Sun Pharmaceutical Industries Ltd. 👋

Expert Opinions

News & Events

Frequently Asked Questions

What is the share price of Sun Pharmaceutical Industries Ltd.?

What is the market cap of Sun Pharmaceutical Industries Ltd.?

Should I buy Sun Pharmaceutical Industries Ltd. stock now?

What is the 52 week high and low of Sun Pharmaceutical Industries Ltd.?

Is the Sun Pharmaceutical Industries Ltd. stock good to buy?

Is Sun Pharmaceutical Industries Ltd. a good buy for the long term?

Is Sun Pharmaceutical Industries Ltd. overvalued or undervalued?

What is the PE and PB ratio of Sun Pharmaceutical Industries Ltd.?